Related Experiment Videos
[Cost-effectiveness analysis in type 2 diabetes patients without hypertension]
Enrique Villarreal-Ríos1, Emma Rosa Vargas-Daza, Liliana Galicia-Rodríguez
1Unidad de Investigación Epidemiológica y en Servicios de Salud, Instituto Mexicano del Seguro Social, Querétaro, México. enrique.villarreal@imss.gob.mx
Revista Medica Del Instituto Mexicano Del Seguro Social
|January 6, 2011
Summary
The SOHDi program for type 2 diabetes patients was less effective and more costly than traditional care. It did not demonstrate cost-effectiveness in improving blood glucose levels under current conditions.
Area of Science:
- Health Economics
- Metabolic Diseases
- Clinical Interventions
Context:
- Type 2 diabetes mellitus (DM2) management requires cost-effective interventions.
- Overweight, obesity, and hypertension are common comorbidities in DM2.
- Evaluating novel programs like SOHDi is crucial for optimizing patient care.
Purpose:
- To assess the cost-effectiveness of the SOHDi program for DM2 patients without hypertension.
- To compare the SOHDi program's effectiveness and costs against traditional alternative medical attention (TAMA).
Summary:
- A study of 32 DM2 patients compared the SOHDi program with TAMA, measuring effectiveness by blood glucose levels below 140 mg/dL.
- SOHDi showed lower effectiveness (23.3%) than TAMA (44.8%) and higher average costs ($2202.22 vs. $1930.79).
- Cost-effectiveness analysis indicated SOHDi was less efficient, with higher costs per percentage of improved blood glucose control.
Impact:
- The SOHDi program, in its current form, is not a cost-effective alternative for managing type 2 diabetes.
- Findings suggest a need for program modification or re-evaluation of its operational conditions.
- This study informs healthcare providers and policymakers on resource allocation for diabetes management programs.
Related Concept Videos
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...